POST Online Media Lite Edition



 

India's Cipla launching coronavirus treatment drug Ciplenza in August

Christian Fernsby |
India's pharmaceutical company Cipla Friday announced it has received regulatory approval from the drug controller general of India (DCGI) for launching Favipiravir in the country to be sold under the brand name Ciplenza for restricted emergency use for the treatment of coronavirus patients.

Article continues below



Topics: CIPLA   

The company said it will commercially launch Ciplenza in the first week of August and each tablet has been priced less than a dollar.

Ciplenza has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology.

India on Friday reported the number of coronavirus cases in the country have reached 1,287,945 including 30,601 deaths. Globally India is the third worst-hit country due to the coronavirus pandemic.


What to read next

Cipla to buy two U.S. pharma businesses for $550 million
Pharma giant Cipla to establish JV with Chinese company
BP sells partial stake in Castrol India